Valuation
- Market cap
- 1,274,848,000
- Revenue TTM
- $0
- Net income TTM
- $-209,840,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 692,800
- Avg volume
- 540,846
- Day's range
- $19.59 – $20.76
- Shares out
- 61,736,000
- Stochastic %K
- 31%
- Beta
- 1.43
- Analysts
- Strong Sell
- Price target
- $46.89
Company profile
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the...
Show more
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 781 281 9020
- Website
- https://www.damoratx.com
- Address
- Building 23, Suite 105 221 Crescent Street, Waltham, United States
Latest news
No headlines yet.
